Dr. Sara Allstadt Frazier’s research focuses on advancing novel therapeutics into clinical trials. She works to investigate therapies that advance cancer treatment and incorporate seamlessly into the clinic. She is currently investigating the thiazolidinedione class of drugs and their potential anti-cancer effects through their interaction with peroxisome proliferator activated receptors. BACKGROUND Dr. Frazier graduated from the Auburn University College of Veterinary Medicine in 2002. After graduation, she returned home to general practice in South Alabama, leaving to pursue her dream of becoming a specialist after three years as a small town general practice veterinarian. After completing an internship in small animal medicine and surgery and an oncology specialty internship, she completed her Residency in Medical Oncology at the University of California-Davis and achieved board-certification in the American College of Veterinary Internal Medicine specialty of Oncology. She joined the faculty at UC Davis in 2010 and remained there until August of 2012, when she moved east to join the faculty at the University of Tennessee. Dr. Frazier enjoys the diversity of the academic environment- the invigoration of inspiring students to be fantastic veterinarians, the challenges and successes of patient interaction, the advantage of having multiple specialists working alongside each other, along with the thrill of advancing research for the betterment of cancer treatment in both animals and humans alike.
Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs (with D S. McKemie, T A. Guerrero, H Lachapelle, K A. Skorupski, P H. Kass, and C O. Rodriguez CO Jr.), Veterinary and Comparative Oncology (2012)